Apt21-2

Apt21-2 is a 2'-fluorine-modified RNA (2'-F-RNA) aptamer designed to target and neutralize Interleukin-17A (IL-17A). IL-17A is a key pathogenic cytokine involved in the development of autoimmune arthropathies, including axial spondyloarthritis and rheumatoid arthritis. By binding specifically to IL-17A, Apt21-2 inhibits the cytokine's interaction with its receptor (IL-17RA), thereby blocking downstream inflammatory signaling. In preclinical in vitro studies using peripheral blood mononuclear cells (PBMCs) and patient-derived fibroblast-like synoviocytes (FLSs), Apt21-2 has demonstrated the ability to suppress IL-17A-induced secretion of pro-inflammatory markers such as IL-6 and matrix metalloproteinase-13 (MMP-13) with efficacy comparable to the monoclonal antibody secukinumab. It is being explored as a potential alternative to antibody-based therapies due to advantages in stability and reduced immunogenicity.

Other names

2'-F-RNA aptamer Apt21-2anti-IL-17A aptamer Apt21-2anti-IL17A aptamer Apt21-2anti-IL 17A aptamer Apt21-2